A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma

[1]  Jing Zhang,et al.  Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis , 2014, Leukemia & lymphoma.

[2]  M. Ziepert,et al.  A NEW PROGNOSTIC MODEL TO ASSESS THE RISK OF CNS DISEASE IN PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMA , 2013 .

[3]  M. Dimopoulos,et al.  Re‐evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents , 2013, Hematological oncology.

[4]  J. Delabie,et al.  Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  K. Imrie,et al.  Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B‐cell lymphoma treated in the rituximab era: a single centre experience and review of the literature , 2012, British journal of haematology.

[6]  L. Gordon,et al.  Lack of benefit of central nervous system prophylaxis for diffuse large B‐cell lymphoma in the rituximab era , 2012, Cancer.

[7]  T. Siegal,et al.  CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom? , 2012, Blood reviews.

[8]  W. C. Chan,et al.  The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B‐cell lymphoma , 2012, British journal of haematology.

[9]  N. Schmitz,et al.  CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  A. Huitema,et al.  Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma , 2012, Leukemia & lymphoma.

[11]  Kazuya Sato,et al.  Central nervous system event in patients with diffuse large B‐cell lymphoma in the rituximab era , 2012, Cancer science.

[12]  T. Molina,et al.  Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial , 2011, The Lancet.

[13]  D. Ennishi,et al.  CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  K. Morris,et al.  Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma , 2011, Cancer.

[15]  X. Hou,et al.  Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab , 2011, Annals of Hematology.

[16]  Y. Ishigatsubo,et al.  Central nervous system involvement in diffuse large B‐cell lymphoma , 2010, European journal of haematology.

[17]  R. Gascoyne,et al.  Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  E. Thiel,et al.  Penetration of ifosfamide and its active metabolite 4-OH-ifosfamide into cerebrospinal fluid of patients with CNS malignancies , 2010, Cancer Chemotherapy and Pharmacology.

[19]  F. Cavalli,et al.  Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more. , 2009, Seminars in oncology.

[20]  A. Ferreri,et al.  Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options , 2009, Hematological oncology.

[21]  N. Schmitz,et al.  CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). , 2009, Blood.

[22]  K. Notohara,et al.  Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience , 2009, International journal of hematology.

[23]  J. Friedberg,et al.  Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Y. Bang,et al.  Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement , 2009, Annals of Hematology.

[25]  A. Ng,et al.  Diffuse large B-cell lymphoma. , 2007, Seminars in radiation oncology.

[26]  S. Kvaløy,et al.  Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  W. Grody,et al.  36 – Diffuse Large B-Cell Lymphoma , 2006 .

[28]  J. Seymour,et al.  Primary non-Hodgkin's lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers. , 2006, Clinical lymphoma & myeloma.

[29]  P. Gaulard,et al.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  T. Molina,et al.  Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  T. Molina,et al.  Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. , 2003, Blood.

[32]  F. Cavalli,et al.  Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  S. Kvaløy,et al.  Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  J. Streater,et al.  Intrathecal Chemotherapy alone is Inadequate Central Nervous System Prophylaxis in Patients with Intermediate-grade Non-Hodgkin's Lymphoma , 2002, Leukemia & lymphoma.

[35]  H. Tilly,et al.  Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients , 2000 .

[36]  H. Tilly,et al.  Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  R. Murphy,et al.  Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration , 2000, Cancer Chemotherapy and Pharmacology.

[38]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[39]  F. Gherlinzoni,et al.  Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience. , 1999, Leukemia & lymphoma.

[40]  P. Mclaughlin,et al.  Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. , 1998, Blood.

[41]  A. Hagenbeek,et al.  For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  H. Kantarjian,et al.  The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia , 1997, Leukemia.

[43]  H. Kimelberg,et al.  Distribution and degradation of [3H]methotrexate after intravenous and cerebral intraventricular injection in primates. , 1977, Cancer research.

[44]  J. Bertino,et al.  Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates. , 1969, The Journal of clinical investigation.

[45]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .